Nov 12, 2018
Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
Sep 24, 2018
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Apr 25, 2018
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
Apr 19, 2018
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
Feb 20, 2018
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
Nov 28, 2017
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
Nov 21, 2017
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Nov 16, 2017
Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD
Oct 30, 2017
Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017
Sep 20, 2017
Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva
Sep 19, 2017
Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 19, 2017
Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
Sep 18, 2017
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
Sep 18, 2017
Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)
Sep 05, 2017
Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference